AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AtriCure, Inc. (NASDAQ:ATRC) have earned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $48.50.

Several analysts have issued reports on the company. UBS Group dropped their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Weiss Ratings raised AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st.

AtriCure Stock Down 0.2%

Shares of ATRC stock opened at $43.49 on Friday. The firm has a fifty day moving average of $33.57 and a 200-day moving average of $31.43. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure has a 12-month low of $25.36 and a 12-month high of $44.38. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of 207.11 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities research analysts predict that AtriCure will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Karen Prange sold 3,564 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Sven Wehrwein sold 25,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the transaction, the director directly owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,246 shares of company stock valued at $1,777,845 over the last ninety days. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of AtriCure in the second quarter valued at about $125,198,000. Marshall Wace LLP raised its holdings in AtriCure by 63.4% during the fourth quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after acquiring an additional 354,281 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in AtriCure during the second quarter valued at approximately $9,388,000. Wellington Management Group LLP boosted its position in AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after purchasing an additional 322,818 shares during the last quarter. Finally, First Light Asset Management LLC grew its stake in AtriCure by 32.0% in the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock valued at $46,501,000 after purchasing an additional 285,083 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.